With Ophthotech Corp (NASDAQ: OPHT) shares down sharply this morning after Regeneron (NASDAQ: REGN) announced that Rinucumab (anti-PDGF-beta) co-formulated with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Hot Comments Trader Talk

Leerink Partners Reiterates Outperform on Regeneron (REGN) October 3, 2016 8:48 AM Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMDSeptember 30, 2016 10:16 AM Ophthotech Corp (OPHT) on Watch After Regeneron (REGN) Reports Eylea/Rinucumab Combo DataSeptember 30, 2016 8:05 AM